Rogel Cancer Center names Kaffenberger to deputy director role

11:00 AM

Author | Nicole Fawcett

Rogel Cancer Center with trees and blue sky
Rogel Cancer Center building

ANN ARBOR, Michigan – The University of Michigan Rogel Cancer Center has named Samuel Kaffenberger, MD, as deputy director for cancer clinical services, a role that complements his current position as senior medical director for cancer services at Michigan Medicine. Kaffenberger was also named medical director of clinical operations for the cancer center.  

The combined roles will help ensure greater alignment and integration of clinical operations with research, training and patient care.

Kaffenberger is clinical associate professor of urology at Michigan Medicine. A graduate of the University of Pittsburgh School of Medicine, he completed his residency in urologic surgery at Vanderbilt University Medical Center. He then completed a Society of Urologic Oncology-certified fellowship in urologic oncology at Memorial Sloan Kettering Cancer Center, where he was chief fellow. 

His clinical and research interests are focused on the surgical care of patients with all urologic malignancies, including cancers of the kidney, testis, prostate and bladder. 

Kaffenberger was named associate director for clinical operations at Rogel in 2024. As deputy director and medical director, Kaffenberger will continue to strengthen clinical operations, expand access and enhance clinical research opportunities at the primary Rogel Cancer Center clinics and affiliated sites. He will collaborate with colleagues to support statewide network expansion. Kaffenberger will also serve as a member of the Rogel senior leadership council and executive committee. 

“Under Dr. Kaffenberger’s leadership, I am confident the Rogel Cancer Center will identify and pursue emerging opportunities and initiatives as we work together to expand and enhance access to the highest quality cancer care and improve outcomes and quality of life for all cancer patients and survivors in Michigan,” said Eric R. Fearon, MD, PhD, director of the Rogel Cancer Center.


More Articles About:

Rogel Cancer Center

In This Story

Samuel Kaffenberger

Samuel D Kaffenberger, MD, FACS

Clinical Associate Professor

Featured News & Stories

Man sits in a medical exam room looking at caregiver whose back is to camera and looks toward a computer screen.
Health Lab

Updated prostate cancer screening guidelines emphasize benefits of early detection

New guidelines for prostate cancer screening focus on early detection and individual risk.
Blue and yellow illustration of DNA helix
Health Lab

New anti-cancer strategy shows promise in preclinical studies

New cancer therapeutic strategy rewires protein interactions to improve efficacy and reduce potential side effects.
Group of men smiling in a field
News Release

How have diagnostic and treatment decisions for prostate cancer changed in recent years?

An analysis of United States data reveals a broad shift away from overtreatment of low-risk prostate cancer. The analysis by University of Michigan Rogel Cancer Center researchers, indicates a shift toward surveillance in response to concerns of overdiagnosis and overtreatment that have hindered screening in the recent past.
Perforin increases endosomal-mitochondrial contact sites in tumor cells. Left is without perforin; right has perforin.
Health Lab

Immune system protein is a cancer killer on its own, new study shows

New study finds perforin can kill cancer tumor cells even when major granzymes were missing.
Three people stand arm in arm with backs to camera studying a wall of family mementos
Health Lab

Online resources and coaching helped people seek genetic testing for cancer

New study from researchers at the University of Michigan Rogel Cancer Center showed an online resource and phone-based coaching both helped increase rates of genetic testing.
cancer cell blue yellow
Health Lab

‘Molecular glue’ stabilizes protein that inhibits development of non-small cell lung cancer and uterine cancer

University of Michigan researchers found a new protein target PP2A and developed a drug to treat non-small cell lung cancers that have KRAS mutations.